公司資料
Relay Therapeutics 股價、新聞與催化劑
- 股票代碼:
- RLAY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
20.67 USD (+4.08%)
收盤價
最後更新: 2026年8月17日
3.42B USD
市值
股價為何變動
As of Aug 17, 2026, RLAY closed up 4.08% at $20.67. No new same-company headline was identified in the current news window.
公司概覽
Structure-Based Precision Medicine
Relay Therapeutics develops small-molecule medicines using a platform designed to model protein motion and identify druggable conformations. Its clinical portfolio focuses on genetically defined cancers and diseases driven by difficult-to-target proteins.
Zovegalisib in Breast Cancer
Zovegalisib is a mutant-selective PI3Kα inhibitor intended to preserve activity against oncogenic PIK3CA mutations while limiting inhibition of wild-type PI3Kα. It is being evaluated with fulvestrant in the Phase 3 ReDiscover-2 trial for previously treated HR-positive, HER2-negative advanced breast cancer.
Frontline Combination Strategy
Relay selected zovegalisib with atirmociclib and endocrine therapy as its preferred triplet for first-line endocrine-sensitive metastatic breast cancer. The approach combines selective PI3Kα and CDK4 inhibition while Relay retains global rights to zovegalisib.
Vascular Anomalies
Because activating PI3Kα mutations also drive many vascular anomalies, Relay is evaluating zovegalisib outside oncology. This program broadens the addressable population for the molecule and tests its mutant-selective profile in a genetic disease setting.
NRAS Program
RLY-8161 is an NRAS-selective molecule in Phase 1/2 development for NRAS-mutant solid tumors. The program adds a second clinically tested precision-oncology mechanism to Relay’s pipeline.
未來催化劑
- Initial zovegalisib clinical data in vascular anomalies expected at the ISSVA meeting.
- Initiation of a Phase 3 first-line breast-cancer trial of zovegalisib, atirmociclib and endocrine therapy expected in early 2027, subject to regulatory feedback.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。